ADIA Nutrition Appoints Dr. Richard Edwards, DO as Second Medical Director
Adia Nutrition (OTC Pink: ADIA) has appointed Dr. Richard Edwards, DO, as its second Medical Director, joining Dr. Monica Sher, MD. This expansion aims to enhance the company's capabilities in autologous Hematopoietic Stem Cell Transplantation (aHSCT). The company is now focusing on recruiting oncologists to administer aHSCT treatments and developing protocols based on global best practices. The medical directors will be involved in patient evaluation and determining treatment settings. CEO Larry Powalisz emphasized that this appointment will accelerate progress towards opening their first clinic, showcasing Adia's commitment to advancing innovative treatments in the field.
Adia Nutrition (OTC Pink: ADIA) ha nominato Dr. Richard Edwards, DO come suo secondo Direttore Medico, unendosi al Dr. Monica Sher, MD. Questa espansione mira a potenziare le capacità dell'azienda nella trapianto di cellule staminali ematopoietiche autologhe (aHSCT). L'azienda si sta ora concentrando sul reclutamento di oncologi per amministrare i trattamenti aHSCT e sviluppare protocolli basati sulle migliori pratiche globali. I direttori medici parteciperanno alla valutazione dei pazienti e alla determinazione delle impostazioni terapeutiche. Il CEO Larry Powalisz ha sottolineato che questa nomina accelererà il progresso verso l'apertura della loro prima clinica, dimostrando l'impegno di Adia nel promuovere trattamenti innovativi nel settore.
Adia Nutrition (OTC Pink: ADIA) ha nombrado al Dr. Richard Edwards, DO como su segundo Director Médico, uniéndose a la Dra. Monica Sher, MD. Esta expansión tiene como objetivo mejorar las capacidades de la empresa en trasplantes de células madre hematopoyéticas autólogas (aHSCT). La empresa ahora se está enfocando en reclutar oncólogos para administrar tratamientos aHSCT y desarrollar protocolos basados en las mejores prácticas globales. Los directores médicos estarán involucrados en la evaluación de pacientes y en la determinación de los entornos de tratamiento. El CEO Larry Powalisz enfatizó que esta designación acelerará el progreso hacia la apertura de su primera clínica, demostrando el compromiso de Adia con el avance de tratamientos innovadores en el campo.
Adia Nutrition (OTC Pink: ADIA)는 Dr. Richard Edwards, DO를 두 번째 의료 이사로 임명하며 Dr. Monica Sher, MD와 함께하게 되었습니다. 이번 확장은 자체 유래 조혈모세포 이식(aHSCT) 분야에서 회사의 역량을 강화하는 것을 목표로 하고 있습니다. 회사는 현재 종양 전문의를 모집하여 aHSCT 치료를 시행하고, 글로벌 최우수 사례를 바탕으로 프로토콜을 개발하는 데 집중하고 있습니다. 의료 이사들은 환자 평가 및 치료 환경 결정을 담당하게 됩니다. CEO인 Larry Powalisz는 이번 임명이 첫 클리닉 개장을 향한 진행을 가속화할 것이라고 말하며, Adia의 혁신적인 치료 발전에 대한 의지를 보여주고 있습니다.
Adia Nutrition (OTC Pink: ADIA) a nommé Dr. Richard Edwards, DO comme son deuxième Directeur Médical, rejoignant Dr. Monica Sher, MD. Cette expansion vise à renforcer les capacités de l'entreprise dans le domaine de la transplantation de cellules souches hématopoïétiques autologues (aHSCT). L'entreprise se concentre maintenant sur le recrutement d'oncologues pour administrer les traitements aHSCT et développer des protocoles basés sur les meilleures pratiques mondiales. Les directeurs médicaux seront impliqués dans l'évaluation des patients et la détermination des modalités de traitement. Le PDG Larry Powalisz a souligné que cette nomination accélérera le progrès vers l'ouverture de leur première clinique, démontrant l'engagement d'Adia à faire avancer des traitements innovants dans le domaine.
Adia Nutrition (OTC Pink: ADIA) hat Dr. Richard Edwards, DO zum zweiten Medizinischen Direktor ernannt, um Dr. Monica Sher, MD zu ergänzen. Diese Expansion zielt darauf ab, die Fähigkeiten des Unternehmens in der autologen hämatopoetischen Stammzelltransplantation (aHSCT) zu verbessern. Das Unternehmen konzentriert sich nun auf die Rekrutierung von Onkologen, um aHSCT-Behandlungen durchzuführen und Protokolle basierend auf globalen Best Practices zu entwickeln. Die medizinischen Leiter werden an der Patientenbewertung und der Festlegung der Behandlungssettings beteiligt sein. CEO Larry Powalisz betonte, dass diese Ernennung den Fortschritt zur Eröffnung ihrer ersten Klinik beschleunigen wird, was das Engagement von Adia für die Weiterentwicklung innovativer Behandlungen in diesem Bereich unterstreicht.
- Appointment of Dr. Richard Edwards as second Medical Director, expanding medical expertise
- Progress towards opening the first clinic for aHSCT treatments
- Plans to recruit oncologists to administer treatments
- Development of tailored protocols based on global best practices (over 10,000 patients treated worldwide)
- None.
WINTER PARK, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is excited to announce the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutrition’s commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT).
Dr. Edwards, a distinguished osteopathic physician, complements Dr. Sher’s medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutrition’s mission to deliver comprehensive and individualized treatment plans.
Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutrition’s clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care.
In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.
“We are thrilled to welcome Dr. Edwards to our team,” said CEO Larry Powalisz. “His expertise and osteopathic perspective will be invaluable to Adia’s Medical Division. This new appointment will accelerate the progress towards opening our first clinic.”
Adia Nutrition remains dedicated to pushing the boundaries of medical excellence and patient care. The addition of Dr. Edwards and the forthcoming recruitment of oncologists represent significant strides toward achieving this goal. The company is eager to implement cutting-edge protocols and begin offering aHSCT treatments to eligible patients.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.biolete.com
Website: www.cementfactory.com
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65188a62-7a09-4d60-91a7-5ce799fb8927
FAQ
Who is the new Medical Director appointed by Adia Nutrition (ADIA)?
What is Adia Nutrition's (ADIA) focus in stem cell treatments?
What are the next steps for Adia Nutrition (ADIA) after appointing Dr. Edwards?
How will Adia Nutrition (ADIA) determine patient eligibility for aHSCT treatments?
